KKIAMRE Activators encompass a variety of chemical compounds that indirectly stimulate the functional activity of KKIAMRE through multiple signaling pathways primarily associated with the modulation of cyclic AMP (cAMP) and protein kinase A (PKA). Forskolin directly activates adenylate cyclase, leading to an increase in cAMP levels, and subsequently activates PKA, which may result in the phosphorylation and activation of KKIAMRE if it is a substrate for this kinase. Similarly, compounds like Rolipram and IBMX inhibit phosphodiesterase activity, preventing cAMP degradation and enhancing the potential for KKIAMRE activation through PKA-dependent phosphorylation. Adrenergic agonists such as Epinephrine and Isoproterenol, as well as neurotransmitters like Dopamine, activate G-protein-coupled receptors that stimulate adenylate cyclase, increasing cAMP and PKA activity, which in turn could lead to the phosphorylation and enhancement of KKIAMRE activity.Histamine, through its interaction with H2 receptors, and PGE2 through EP receptors, both lead to adenylate cyclase stimulation and elevated cAMP levels, providing additional pathways for PKA to potentially phosphorylate and activate KKIAMRE.
Cholera toxin, by constitutively activating adenylate cyclase through ADP-ribosylation of the Gs alpha subunit, also raises cAMP and activates PKA, which could then enhance KKIAMRE function through phosphorylation. Hormonal signals such as Glucagon, which operates via its receptor to activate adenylate cyclase, contribute to the same cAMP-dependent PKA signaling mechanism, potentially leading to the enhanced activity of KKIAMRE through phosphorylation. Phosphodiesterase inhibitors like Zardaverine and Luteolin increase cAMP levels, providing a sustained signal for PKA activation which could in turn phosphorylate and activate KKIAMRE, thereby enhancing its role in cellular signaling processes. Collectively, these KKIAMRE Activators operate through a network of cAMP-PKA signaling, converging on the potential activation of KKIAMRE through kinase-mediated phosphorylation without directly influencing its expression levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels, which can lead to the activation of PKA. PKA phosphorylates specific proteins, potentially including KKIAMRE, thereby enhancing its activity within cellular signaling pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase-4 (PDE4), preventing the breakdown of cAMP. Elevated cAMP levels can activate PKA, which could phosphorylate and activate KKIAMRE if it is a PKA substrate. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increased cAMP levels, potentially enhancing KKIAMRE activity through PKA-mediated phosphorylation if KKIAMRE is a substrate of PKA. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds adrenergic receptors, stimulating adenylate cyclase, and increasing cAMP levels, which may lead to the activation of KKIAMRE through PKA-mediated pathways if KKIAMRE is influenced by these pathways. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine, through its action on dopamine receptors, can increase cAMP levels, potentially influencing the phosphorylation state and activity of KKIAMRE via PKA if KKIAMRE is part of this signaling cascade. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol acts as an agonist at beta-adrenergic receptors, leading to increased cAMP and subsequent activation of PKA, which could phosphorylate and enhance KKIAMRE activity if KKIAMRE is a PKA target. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can stimulate adenylate cyclase via H2 receptors, increasing cAMP and potentially enhancing KKIAMRE activity through PKA-mediated phosphorylation if KKIAMRE is impacted by this pathway. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 binds to its G-protein-coupled receptors (EP receptors), potentially leading to increased intracellular cAMP levels and activation of PKA, which may phosphorylate KKIAMRE, enhancing its activity if KKIAMRE is a PKA substrate. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine is a phosphodiesterase inhibitor that leads to increased levels of cAMP, potentially enhancing the activity of KKIAMRE via PKA-mediated phosphorylation if KKIAMRE is involved in these pathways. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $27.00 $51.00 $101.00 $153.00 $1925.00 | 40 | |
Luteolin inhibits phosphodiesterase, enhancing cAMP levels, which could activate PKA, leading to phosphorylation and potential activation of KKIAMRE if KKIAMRE is a target for PKA. | ||||||